• About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
ENG
  • KOR
  • ENG
  • About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
PR
STCube is dedicated to developing precision-driven immunotherapies,
bringing new hope to more cancer patients.
  • Press Release
  • Notices
Press Release
  • Press Release
  • Notices
Press Release
  • Home
  • PR
  • Press Release
  • 에스티큐브, AACR서 ‘대장암의 새로운 바이오마커’ 발표…BTN1A1 연구성과 소개
    2025.03.26
  • 에스티큐브, 대장암 1b/2상 IND 승인…바이오마커 기반 임상 본격화
    2025.03.21
  • [KBR] Novel immunotherapy nelmastobart shows promise in MSS colorectal..
    2025.02.28
  • [히트뉴스] "진정한 'First-in-Class'… K-키트루다, 우리가 만든다"
    2025.02.25
  • [더벨] 적자 줄인 에스티큐브, 임상 속도에도 화장품 사업 '든든'
    2025.02.24
  • 에스티큐브, 법차손 이슈 해결하고 신약개발 전념…"임상연구 성과 자신"
    2025.02.19
  • 에스티큐브, 대장암 1b/2상 IND 식약처 제출…바이오마커 기반 임상으로 전환
    2025.02.18
  • [딜사이트] 유승한 에스티큐브 CSO "면역항암제 기술수출 도전"
    2025.01.23
  • 에스티큐브 신약, 대장암서 생존율 개선 입증…표준치료 대비 PFS 연장 '이점'
    2025.01.22
6 7 8 9 10

2201, Trade Center Trade Tower, 511 Yeongdong-daero, Gangnam-gu, Seoul, Republic of Korea

Tel : +82-2-551-3370

Copyright by STCube All Rights Reserved.